In what's set to be one of the biggest UK Private Equity deals so far this year, we’re delighted to have assisted Dechra Pharmaceuticals with shareholder documentation for its £4.5bn agreed takeover bid from Swedish private equity firm EQT.
Dechra is recognised as a global leader in therapeutic areas such as endocrinology and topical dermatology, as well as being an innovator in specialisations such as the treatment of equine lameness and differentiated generics. Dechra is ranked seventh globally by revenues, with operations in 26 countries and over 2,400 employees.
With medical innovation accelerating and pet ownership increasing, the animal health sector is expected to benefit from long-term growth and EQT believes Dechra is well positioned to participate in this significant opportunity.
With thanks to our wonderful clients at DLA Piper, and wishing the company every future success.